Theratechnologies (TSE:TH) had its price target cut by research analysts at Royal Bank of Canada from C$7.00 to C$6.00 in a report issued on Wednesday, BayStreet.CA reports. The firm presently has a “sector perform” rating on the stock. Royal Bank of Canada’s price objective suggests a potential upside of 24.48% from the stock’s previous close.

A number of other equities analysts have also recently commented on the stock. National Bank Financial cut their target price on shares of Theratechnologies from C$11.25 to C$8.25 and set a “sector perform” rating on the stock in a report on Friday, July 12th. Mackie cut their target price on shares of Theratechnologies from C$8.15 to C$7.00 and set a “hold” rating on the stock in a report on Friday, July 12th. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of C$8.75.

Shares of Theratechnologies stock traded down C$0.70 during trading on Wednesday, reaching C$4.82. The company’s stock had a trading volume of 278,900 shares, compared to its average volume of 129,380. The company has a 50-day moving average price of C$5.38 and a two-hundred day moving average price of C$6.30. The firm has a market cap of $370.91 million and a PE ratio of -76.51. Theratechnologies has a fifty-two week low of C$4.71 and a fifty-two week high of C$9.74. The company has a current ratio of 2.69, a quick ratio of 2.09 and a debt-to-equity ratio of 159.35.

Theratechnologies (TSE:TH) last announced its earnings results on Thursday, July 11th. The company reported C($0.06) EPS for the quarter. The firm had revenue of C$20.92 million for the quarter, compared to analyst estimates of C$26.00 million. On average, analysts predict that Theratechnologies will post 0.14 earnings per share for the current fiscal year.

About Theratechnologies

Theratechnologies Inc, a specialty pharmaceutical company, addresses unmet medical needs to promote healthy living and improve quality of life among HIV patients. It offers EGRIFTA, for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy in Canada and the United States; and Trogarz, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients in the United States.

Recommended Story: Dead Cat Bounce

Analyst Recommendations for Theratechnologies (TSE:TH)

Receive News & Ratings for Theratechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theratechnologies and related companies with's FREE daily email newsletter.